Atogepant - CISMeF

Preferred Label : Atogepant;

NCIt related terms : Qulipta;

NCIt definition : An orally bioavailable calcitonin gene-related peptide (CGRP) receptor antagonist that can be used in the preventive treatment of migraines. Upon oral administration, atogepant targets, binds to and blocks the activity of CGRP receptor, thereby preventing CGRP-mediated signaling. By blocking the CGRP-mediated pathways, atogepant is able to relieve or prevent migraine. CGRP-mediated signaling plays a key role in migraine pathogenesis.;

UNII : 7CRV8RR151;

InChIKey : QIVUCLWGARAQIO-OLIXTKCUSA-N;

CAS number : 1374248-81-3;

Drug name : Qulipta;

NCI Metathesaurus CUI : CL972012;

Détails

Origin ID

C167018;

UMLS CUI

C5238205;

Currated CISMeF NLP mapping
- Atogepant [SMS substance]
- atogepant [MeSH Supplementary Concept]
- atogepant [MeSH concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- atogepant [MeSH Supplementary Concept]
- atogepant [ATC Code]
Validated automatic mappings to BTNT
- atogepant [ATC Code]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients